Muscular Dystrophy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Muscular Dystrophy stocks.

Muscular Dystrophy Stocks Recent News

Date Stock Title
May 2 DYN Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 2 SMMT Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript
May 2 WVE Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
May 2 SRPT Q1 2024 Sarepta Therapeutics Inc Earnings Call
May 2 SRPT Sarepta Therapeutics Inc (SRPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
May 2 SMMT Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
May 2 SMMT Q1 2024 Summit Therapeutics Inc Earnings Call
May 2 SMMT Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
May 1 SRPT Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 1 SRPT Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
May 1 SRPT Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
May 1 SRPT Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
May 1 SRPT Sarepta Therapeutics jumps 5% on Q1 beats
May 1 SRPT Sarepta Therapeutics Non-GAAP EPS of $0.73 beats by $0.43, revenue of $413.5M beats by $43.02M
May 1 SRPT Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
May 1 PTCT PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
May 1 SRPT 1 Top Growth Stock to Buy and Hold for 10 Years
May 1 BNTC Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
May 1 SMMT Summit Therapeutics Non-GAAP EPS of -$0.05 beats by $0.01
May 1 SMMT Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
Muscular Dystrophy

Muscular dystrophy (MD) is a group of muscle diseases that results in increasing weakening and breakdown of skeletal muscles over time. The disorders differ in which muscles are primarily affected, the degree of weakness, how fast they worsen, and when symptoms begin. Many people will eventually become unable to walk. Some types are also associated with problems in other organs.The muscular dystrophy group contains thirty different genetic disorders that are usually classified into nine main categories or types. The most common type is Duchenne muscular dystrophy (DMD) which typically affects males beginning around the age of four. Other types include Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. They are due to mutations in genes that are involved in making muscle proteins. This can occur due to either inheriting the defect from one's parents or the mutation occurring during early development. Disorders may be X-linked recessive, autosomal recessive, or autosomal dominant. Diagnosis often involves blood tests and genetic testing.There is no cure for muscular dystrophy. Physical therapy, braces, and corrective surgery may help with some symptoms. Assisted ventilation may be required in those with weakness of breathing muscles. Medications used include steroids to slow muscle degeneration, anticonvulsants to control seizures and some muscle activity, and immunosuppressants to delay damage to dying muscle cells. Outcomes depend on the specific type of disorder.Duchenne muscular dystrophy, which represents about half of all cases of muscular dystrophy, affects about one in 5,000 males at birth. Muscular dystrophy was first described in the 1830s by Charles Bell. The word "dystrophy" is from the Greek dys, meaning "difficult" and troph meaning "nourish". Gene therapy, as a treatment, is in the early stages of study in humans.

Browse All Tags